Psychiatry & Neurology Doctors in Camarillo, CA Accepting Medicare

7 Psychiatry & Neurology doctors found. Showing 1 - 7

Dr. Daniel Patrick Flynn, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 340 Rosewood Ave, Suite A, Camarillo, CA 93010 Phone: 805-388-3663    Fax: 805-388-3663

Lorna M Barte, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1601 Carmen Drive, Suite 106, Camarillo, CA 93010 Phone: 805-389-8111    Fax: 805-389-8188

Jane Yeoun Chung, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 333 N Lantana St, Suite 273, Camarillo, CA 93010 Phone: 805-388-8330    Fax: 805-388-8030

Dr. Celia Maria Woods, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 601 E Daily Dr Ste 110, Camarillo, CA 93010 Phone: 805-485-5051    Fax: 805-278-7945

Dr. Sandor George Dresnin, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 2510 Las Posas Rd, Suite #410, Camarillo, CA 93010 Phone: 818-883-3206

Dr. Diane St. Fleur, M.D. Psychiatry & Neurology - Forensic Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 601 E Daily Dr Ste 110, Camarillo, CA 93010 Phone: 631-513-6676

Dr. William David Goldie, M.D. Psychiatry & Neurology - Neurology with Special Qualifications in Child Neurology Medicare: Medicare Enrolled Practice Location: 3152 Calle De Marejada, Camarillo, CA 93010 Phone: 805-988-0974

News Archive

Discovery Labs plans to file request for hearing over Nasdaq delisting notification

Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

Borrelia infection can cause scleratrophic skin lesions in certain countries

This review summarizes the literature on scleratrophic skin lesions as a manifestation of a Borrelia infection. An association of morphea with Lyme borreliosis LB was mainly reported from Middle-European Countries, Japan and South America. B. afzelii has been identified predominantly from the chronic skin lesions of acrodermatitis chronica atrophicans (ACA) and has been cultivated from morphea lesions in isolated cases.

More states join Go NAPSACC online program to improve health of young children

In 2019, Go NAPSACC will be in 20 states working to improve the health of young children. Developed at the University of North Carolina at Chapel Hill, Go NAPSACC is an online tool that helps child care programs create environments for healthy eating and physical activity in children.

University of Illinois at Chicago awarded $7.2 million to eliminate health disparities

The University of Illinois at Chicago has been awarded a $7.2 million federal grant to establish the UIC Center of Excellence in Eliminating Health Disparities.

Read more Medical News

› Verified 3 days ago